Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Oral administration of arsenic + ATRA effective for APML
Zhu HH et al. Lancet Oncol. 2018;19:871-9.
Key clinical point: Acute promyelocytic leukemia can be effectively treated with a chemotherapy-free oral regimen.
Major finding: The 2-year event-free survival was 97% with oral arsenic/ATRA versus 94% with IV arsenic trioxide/ATRA.
Study details: Randomized open-label phase 3 trial of 109 patients with APML.
Disclosures: The National Natural Science Foundation of China, the Beijing Municipal Science and Technology Commission, and the National Key R&D Program of China supported the study. The investigators reported having no financial disclosures.
Source: Zhu HH et al. Lancet Oncol. 2018;19:871-9.
Citation:
Zhu HH et al. Lancet Oncol. 2018;19:871-9.